Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Harvard Bioscience (HBIO) Gross Margin (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Gross Margin for 16 consecutive years, with 58.38% as the latest value for Q3 2025.

  • On a quarterly basis, Gross Margin rose 28.0% to 58.38% in Q3 2025 year-over-year; TTM through Sep 2025 was 56.94%, a 147.0% decrease, with the full-year FY2024 number at 58.18%, down 68.0% from a year prior.
  • Gross Margin was 58.38% for Q3 2025 at Harvard Bioscience, up from 56.4% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 61.2% in Q1 2023 to a low of 45.21% in Q3 2022.
  • A 5-year average of 56.84% and a median of 57.18% in 2021 define the central range for Gross Margin.
  • Peak YoY movement for Gross Margin: crashed -977bps in 2022, then soared 1285bps in 2023.
  • Harvard Bioscience's Gross Margin stood at 59.17% in 2021, then fell by -6bps to 55.7% in 2022, then increased by 4bps to 57.99% in 2023, then decreased by -2bps to 57.06% in 2024, then increased by 2bps to 58.38% in 2025.
  • Per Business Quant, the three most recent readings for HBIO's Gross Margin are 58.38% (Q3 2025), 56.4% (Q2 2025), and 55.96% (Q1 2025).